Accelerated · Integrative Drug Development
You have the science.
We have the speed.
LucasPye Bio is the CDMO built for innovative therapies. One partner driving discovery, CMC, IND-enabling work and clinical execution — so you can build the company while we run the program.
- 6–7 yr
- Bench to bedside vs. 12–15 yr traditional
- 30–40%
- Lower total development investment
- ~150%
- Projected 5-yr ROI vs. ~50% benchmark
The LPB Promise
Half the time. Half the capital. Bench to bedside under one integrated network.
The problem
Fragmentation is burning
your runway.
When CDMOs, CROs and regulatory consultants don’t talk to each other, tech transfer alone averages 14 months. Data gets lost. Investors get impatient. Costly delays don’t just hit your timeline — they hit your leverage at the next raise.
12–15 yr
Traditional timelines
Decade-plus development defers investor returns past fund horizons.
14 mo.
Tech-transfer drag
Vendor handoffs across CDMOs, CROs and consultants cost months per transition.
High CAPEX
Stainless-steel burden
Legacy facility costs are out of reach for most seed-stage biotechs.
The solution
One partner. Full lifecycle. Bench to bedside.
Discovery through clinical execution under one integrated network. Real-time e-documentation replaces paper handoffs. Fewer contracts, consistent data standards, no vendor gaps.
- 01
End-to-end lifecycle
Discovery through clinical execution under one integrated network — not a chain of disconnected vendors.
- 02
Digital documentation
Real-time e-documentation and eClinical dashboards replace paper-based handoffs at every step.
- 03
Seamless tech transfer
Eliminate the vendor gaps that inflate cost, risk and timelines — 8-month transfers vs. 14-month industry average.
- 04
Reduced complexity
One partner network, fewer contracts, consistent data standards from cell line to IND filing.
Economics
Every dollar saved is another month before your next raise.
Single-use disposable manufacturing, magnetic-bead processes and a tightly managed partner network combine into a material reduction in the capital required to reach IND.
- 5–17%
- CAPEX reduction
- 18–40%
- COGS reduction
- 30–40%
- Total dev. savings
Illustrative projection based on LPB internal modeling. Detailed scenarios available under NDA.
Technology
The stack traditional CDMOs can’t match.
Single-use manufacturing
No cleaning-validation delays, lower contamination risk, accessible CAPEX without stainless-steel infrastructure.
Automation & digitization
Magnetic-bead processes and continuous workflows lower COGS and accelerate cycle times.
BSL-2 viral vector capacity
One of the few U.S. facilities purpose-built for gene and viral vector drug products.
Real-time data integration
E-documentation and eClinical platforms produce IND-ready packages with no manual reconciliation.
BSL-2 gene therapy programs are a specialty at LPB, not an afterthought.
Ideal partner
Let’s talk before your next fundraise.
We’re long-term, fully integrative partners. We engage best with start-ups that meet a few criteria.
Investor-backed
Board-seat investor in place with capital aligned to a 6–7 year trajectory.
Full executive team
CEO, CFO and CSO operationally ready to engage a CDMO.
First-in-human in 2–3 years
Program stage and budget positioned to reach the clinic within 2–3 years — the IND is the critical document to get there.
Right modality focus
Biologic-based therapeutics, where our platform creates the most leverage.
Budget-qualified
Capital secured or in process to fund a full fixed-scope development package.
Entity age ≤ 7 years
Seed-stage company with a lean, agile team and a long-term mindset.
Next step